Introduction 1
Current diagnostic approaches view schizophrenia and bipolar disorder as distinct 2 psychiatric conditions, despite emerging evidence of significant genetic and 3 phenotypic overlap between the disorders 1 . One of the most obvious challenges to 4 the simple dichotomous view is the existence of the intermediate condition, 5 schizoaffective disorder 2 . The relationship between schizoaffective disorder and 6 schizophrenia and bipolar disorder is uncertain and it has been variously suggested 7 that schizoaffective disorder is a sub-type of either schizophrenia or bipolar disorder, 8
that it reflects comorbidity of schizophrenia and mood disorder, that it is an 9 independent disorder, and, finally, that it lies in the middle of a spectrum that ranges 10 from a predominantly affective disorder to a predominantly psychotic disorder 3 . The 11 latter hypothesis suggests that prototypical bipolar disorder and schizophrenia lie on 12 the extreme ends of a diagnostic spectrum with schizoaffective disorder 13 representing patients who have features of both disorders 4 . Support for this comes 14 from evidence that symptomatic and functional outcomes for schizoaffective 15 disorder are intermediate between schizophrenia and bipolar disorder 5, 6 . More 16 recently it has been proposed that schizophrenia and bipolar disorder lie on a 17 gradient of neurodevelopmental impairment indexed by the extent of cognitive 18 dysfunction, with schizoaffective disorders occupying an intermediate position 1, 7, 8 . 19 Neuropsychological studies that provide support for a diagnostic spectrum have 20 demonstrated increasing severity of impairment from bipolar disorder to 21 schizoaffective disorder to schizophrenia, although these differences were not 22 always significant [9] [10] [11] . In one of the largest studies to date, Hill et al. 10 showed an 23 association between ratings on the Schizo-Bipolar scale 12 and composite cognition scores with more severe impairments amongst those with prominent psychosis and 25 fewer affective symptoms. However, findings from neuropsychological studies of 26 these three disorders have been inconsistent with some studies indicating that 27 performance in schizoaffective disorder is similar to schizophrenia 13 and others 28 indicating no differences between diagnostic groups 14-17 . 29 There are a number of potential explanations for the conflicting findings between 30 studies including differences in the use of covariates and the phase of illness of the 31 study participants. Studies of symptomatic participants with schizophrenia, 32 schizoaffective disorder and bipolar disorder have reported similar levels of 33 impairment 15, 16 . It has been argued that cognitive impairments are state dependent 34
in bipolar disorder and therefore improve during periods of remission. However, 35
more recent research has demonstrated that cognitive impairments are present in 36 euthymic bipolar disorder 18 . Lifetime history of psychosis in bipolar disorder has 37 been identified as another important factor that may influence cognitive function. 38
Studies do not consistently report the proportion of participants with bipolar 39 disorder who have a lifetime history of psychosis despite evidence that the presence 40 or absence of lifetime psychosis differentiates participants with cognitive 41 impairments from those without impairments 17 . Finally, studies often consider 42 schizoaffective disorder as a single group but there is little data to indicate whether 43 differences exist between the subtypes of schizoaffective disorder (depressive or 44 bipolar). The study by Hill et al. 10 showed greater overall impairment in participants 45
with the depressive subtype of schizoaffective disorder than the bipolar subtype, 46 although the differences were not significant. Two smaller studies found no 47 differences between participants with the depressive subtype and participants with 6 schizophrenia but did not consider the bipolar subtype 14, 19 . This suggests 49 amalgamation of both subtype of schizoaffective disorder as a single group may 50 obscure findings. To our knowledge, there have been no published studies that have 51 compared the subtypes of schizoaffective disorder individually to schizophrenia and 52 bipolar disorder. 53
The aim of this study was to test the hypothesis that there is a spectrum of 54 increasing cognitive impairment from bipolar disorder through schizoaffective 55 bipolar to schizoaffective depressive and schizophrenia. We also hypothesised that 56 lifetime frequency and severity of psychotic symptoms (across and within diagnostic 57 boundaries) would be associated with cognitive impairment. These hypotheses were 58 tested in three ways. Firstly, we compared cognitive performance between the 59 diagnostic groups. Secondly, we examined whether cognition can be considered a 60 continuous measure across disorders. For this analysis, the schizophrenia and 61 schizoaffective depressive groups were combined into a single group based on pre-62 existing data suggesting that performance between these groups is equivalent 10, 14, 63 19 . Thirdly, we examined whether cognitive performance is associated with 64 symptoms domains across diagnostic groups. 65
Methods

67
Participants 68
Participants were recruited as part of the Cognition in Mood, Psychosis and 69
Schizophrenia Study (COMPASS), a UK based study that recruits from outpatient 70 clinics. This sample includes participants previously referred to as the Cardiff 71
Cognition in Schizophrenia (COGS) sample (described elsewhere in 20 ). All patient 72 groups were recruited as part of a single study and all aspects of recruitment, response rates, phenotyping and determining diagnosis were equivalent across 74 groups. Participants were interviewed using the Schedules for Clinical Assessment in 75 Neuropsychiatry (SCAN) 21 neurological condition that was likely to impact their ability to participate in the 85 study or had a current substance dependence disorder. 86
One hundred and three control participants were recruited from the community and 87 completed the Mini International Neuropsychiatric Interview (MINI) 23 as a screen 88 for mental disorders. Controls were excluded if they met criteria for schizophrenia or 89 bipolar disorder or there was a family history of these conditions. All participants 90 provided written informed consent and were reimbursed for their participation. 91
Participants were assessed for capacity to provide informed consent by their clinical 92 team and an appropriately trained researcher. The study had UK multi-site NHS 93 ethics approval. 94
Neuropsychological Assessment 95
Cognitive ability was assessed using the Measurement and Treatment Research to 96 Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB 24 ). This battery was designed specifically for use in schizophrenia research 98 but has been shown to be a valid and reliable cognitive measure in bipolar disorder 99 [25] [26] [27] . The MCCB measures seven domains of cognition using ten tasks: 100 Depression, Psychosis and Incongruence. The first three dimensions were included 120 and reflect the severity and frequency of these symptom domains. Current symptoms were rated as the total of the global scores for the Scale for the 122
Assessment of Negative Symptoms (SANS 29 ) and the Scale for the Assessment of 123
Positive Symptoms (SAPS 30 ). Global functioning was measured using the Global 124 Assessment Scale (GAS 31 ). Premorbid IQ was estimated using the National Adult 125
Reading Test. 32 Doses of antipsychotic medication at time of assessment were 126 calculated as olanzapine equivalents 33 and lifetime antipsychotic exposure was 127 calculated from interview and notes data in number of months. Intraclass correlation 128 coefficients for the clinical variables ranged from 0.71 to 0.95. 129
Analysis 130
Comparing cognition between diagnostic groups 131
Statistical analyses to compare the groups were performed using R version 3. pooled standard deviation and used as a measure of effect size. 34 Repeated 140 measures analysis of variance was used to compare profiles of cognitive 141 performance between groups. The within-subject factor was cognitive domain. The 142 effects of medication and symptoms as potential confounding variables were 143 investigated by including olanzapine equivalent dose, duration of antipsychotic 144 exposure, SAPS total scores, SANS total scores, BADDS lifetime depression, 145 educational attainment and parental occupation as covariates. 146
Examining cognition as a dimension across diagnostic groups 147
To test our hypothesis that cognition can be considered a dimensional phenotype 148
showing increasing impairment from bipolar disorder to schizoaffective bipolar to 149 schizophrenia and schizoaffective depressive combined, we conducted an ordinal 150 regression using SPSSv.22 with diagnosis as the outcome, composite cognition score 151 as the predictor and age and sex as covariates. Schizophrenia and schizoaffective 152 depressive were combined given pre-existing data indicating that their degree of 153 impairment is comparable 10, 14, 19 . Diagnosis was coded on an ordinal scale 154 combining schizoaffective depressive and schizophrenia: 0schizoaffective 155 depressive and schizophrenia, 1schizoaffective bipolar, 2bipolar disorder. 156
Cross disorder symptom dimensions and cognitive performance 157
Finally, each BADDS dimension was entered into separate linear regressions as 158 predictors with composite cognition as the outcome using R version 3.1.2. This was 159 initially done across the whole sample and then separately for bipolar disorder / 160 schizoaffective bipolar and schizophrenia / schizoaffective depressive. 161
Results
163
Demographic and clinical variables 164
Demographic and clinical variables are displayed for each diagnostic group in Table  165 1. Groups differed in proportion of males (χ 2 =61.39, p<0.001) with more males 166 observed in the schizophrenia group therefore sex was used as a covariate in all 167
analyses. There were differences in estimated premorbid IQ (F=22.64, p<0.001) and 168 years in education (F=14.19, p<0.001), which were lower for those with 169 schizophrenia and schizoaffective depressive compared to those with bipolar 170 disorder and schizoaffective bipolar. Groups differed on current positive and 171 negative symptoms (SAPS: F=65.96, p=3.13 x 10 -14 ; SANS: F=64. 16, p=7 .58 x 10 -14 ) 172 with lower scores in those with bipolar disorder compared to all other groups. 173
Measures of current global functioning (Global Assessment Scale) differed between 174 groups (F=4.99, p=0.002) with higher scores observed in the bipolar disorder group. 175
Comparing cognition between diagnostic groups 176
There was a significant main effect of diagnosis for all domains of cognition in the 177 analysis of covariance (for example, composite cognition: F(4, 921) = 94.12, 178 p<0.00625, see supplementary table S1 for full results). Figure 1 displays the z scores 179 (marginal means) observed for each group demonstrating an increasing severity of 180 cognitive impairments from controls to bipolar disorder to schizoaffective bipolar to 181 schizophrenia and schizoaffective depressive. 182
Effect sizes for each pairwise comparison between diagnoses for all domains are 183 displayed in Figure 2 . All diagnostic groups were impaired compared to controls 184 across cognitive domains with the exception of social cognition in those with bipolar 185 disorder. The bipolar disorder group was the least impaired of the diagnostic groups, 186 performing 0.5 to 1.25 standard deviations below the mean of the control group 187 across domains (composite cognition: d=1.12, p<0.001). Although the groups were 188 small, we compared bipolar disordertype I (N=68) and bipolar disordertype II 189 (N=10) and found no significant differences between these groups (composite 190 cognition: d=-0.07, p=0.83, see supplementary table S2 for comparisons between 191 domains). The results remained consistent when the analysis was restricted to 192 bipolar disordertype I (see supplementary table S3 ). We also compared bipolar 193 disorder with and without psychosis and found no significant differences between 194 these groups (composite cognition: d=0.34, p=0.2, see supplementary table S4 for 195 comparisons between domains). We note that caution should be applied in the 196 interpretation of the results comparing subgroups of bipolar disorder given the small 197 sample of participants without psychosis (N=19) and with bipolar disordertype II 198 (N=10). The schizoaffective bipolar group was more impaired than the bipolar 199 disorder group although this does not withstand correction for multiple testing 200 (composite cognition: d=0.44, p=0.02). The schizophrenia and schizoaffective 201 depressive groups were the most cognitively impaired and did not differ on any 202 cognitive variable (composite cognition: d=0.07, p=0.90) corroborating our a priori 203 decision to amalgamate these groups for subsequent analyses. These participants 204 were more impaired than those with schizoaffective bipolar (schizophrenia: d=0.52, 205 p<0.001; schizoaffective depressive: d=0.45, p=0.01) and those with bipolar disorder 206 (schizophrenia: d=0.90, p<0.001; schizoaffective depressive: d=0.83,p<0.001). In 207 contrast to other domains, levels of impairment in social cognition between 208 schizoaffective bipolar, schizoaffective depressive and schizophrenia did not differ 209
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In order to test whether between group differences were qualitative or merely 213 quantitative we compared cognitive profiles between diagnostic groups using 214 repeated measures analysis of variance, with cognitive domain included as the 215 within-subject factor. Mau hly's test i di ated that the assu ptio of spheri ity had 216 been violated (χ 2 (20)=360.23, p=3.5 x 10 -64 ) therefore degrees of freedom were corrected using Huynh-Feldt estimates of sphericity. The diagnosis-by-domain 218 interaction was not significant (F=1.62, df=15.50, 3051.33, p=0.06). The analysis was 219 repeated excluding social cognition (given the quantitative differences in this 220 domain) and the diagnosis-by-domain interaction was not significant (F=1.604, 221 df=1.60, 2680.70 p=0.07) indicating that patterns of cognitive ability did not differ by 222 diagnostic group but rather differed quantitatively. 223
We went on to investigate the effects of the potential confounding variables: model. The main effect of diagnostic group on composite cognition remained 240 significant (F(3,694)=8.33, p=1.9 x 10 -5 , see supplementary table S10 for individual domains). After correction for multiple testing, there were significant differences in 242 composite cognition scores between schizoaffective depressive and bipolar disorder 243 (d=0.65, p<0.001) and schizophrenia and bipolar disorder (d=0.58, p<0.001). The 244 relative contributions of each covariate can be found in supplementary table S11. 245
Examining cognition as a dimension across diagnostic groups 246
We used ordinal regression to test whether cognition can be considered a 247 dimensional phenotype across the diagnostic spectrum. This analysis indicated that 248 higher cognitive scores were associated with higher scores on the diagnostic scale 249 (0=schizoaffective depressive / schizophrenia, 1=schizoaffective bipolar and 250 2=bipolar disorder, see supplementary table S12 for full model) supporting a 251 spectrum of increasing impairment from bipolar disorder to schizoaffective bipolar 252 to schizophrenia/schizoaffective depressive. An alternative way of interpreting this 253 result is that among our clinical cases participants with a one standard deviation 254 higher score in composite cognition were almost twice as likely to be diagnosed with 255 schizoaffective bipolar or bipolar disorder compared to schizophrenia (OR = 1.98, p = 256 2.4 x 10 -16 ). Ordinal regression outputs a single odds ratio for the effect of the 257 explanatory variable across all levels of the dependent variable because there is an 258 assumption that the coefficients must be equal across all levels (assumption of 259 proportional odds). This assumption was confirmed using the test of parallel lines in 260 SPSS (χ 2 =4.97, df=3, p=0.17) and by comparing the coefficients for binary regressions 261 for each cut-off point in the scale. The results of the ordinal regression did not 262 change after adjustment for olanzapine equivalent dose, antipsychotic exposure in 263 months and current negative symptoms (OR = 1.63, p = 4.9 x 10 -7 ), although we 264 interpret this result with caution given the proportional odds assumption was 265 violated in this model (χ 2 =26.98, p=1.5 x 10 -4 ). 266
The analysis was followed up with binary regressions between the diagnostic groups 267 (model 1: bipolar disorder and schizoaffective bipolar; model 2: schizoaffective 268 bipolar and schizoaffective depressive/schizophrenia) to compare the gradients from 269 one diagnosis to the next on the scale (see supplementary table S12). The resulting 270 coefficients were equivalent for models 1 and 2. This confirmed that there is a 271 gradient of increasing impairment from bipolar disorder to schizoaffective bipolar to 272 schizophrenia / schizoaffective depressive. 273
Cross disorder symptom dimensions and cognitive performance 274
Median BADDS dimension scores for each diagnostic group are presented in 275 supplementary table S13. Higher scores on the lifetime mania and depression 276 dimensions were associated with better cognitive performance (mania: B=0.010, 277 SE=0.001, p=6.4 x 10 -13 ; depression: B=0.004, SE=0.001, p=.012). Higher scores on 278 the lifetime psychosis dimension predicted poorer cognitive performance (psychosis: 279 B=-0.015, SE=0.002, p=3.2 x 10 -16 ). In the subgroup analyses (bipolar disorder and 280 schizoaffective bipolar only, schizophrenia and schizoaffective depressive only), 281 neither mania nor depression scores predicted performance but higher psychosis 282 scores were associated with lower cognitive scores (schizoaffective bipolar / bipolar 283 disorder: B=-0.010, SE=0.003, p=0.0006; schizoaffective depressive / schizophrenia: 284 B=-0.011, SE=0.003, p=0.0009). All analyses were repeated adjusting for age, sex, 285 antipsychotic exposure in months, olanzapine equivalent dose and current negative 286 symptoms. This did not change the results (see supplementary table S14), although 287 the association between BADDS psychosis scores and cognition in the schizoaffective depressive and schizophrenia subgroup did not survive correction for multiple 289 testing. 290
Discussion 291
We set out to test the hypothesis that there is a spectrum of increasing cognitive 292 impairment from bipolar disorder to schizophrenia and schizoaffective depressive. 293
We report that whilst cognitive profiles were similar across disorders, these 294 impairments increased in severity from bipolar disorder to schizoaffective bipolar to 295 schizophrenia and schizoaffective depressive. There were no differences between 296 schizophrenia and schizoaffective depressive in severity of cognitive impairments. 297
Differences between the groups were not explained by differences in antipsychotic 298 medication or current positive and negative symptoms. In accordance with our 299 hypothesis, ordinal regression modelling provided support for a gradient of 300 increasing cognitive impairment across disorders. Finally we found that higher scores 301 on the BADDS psychosis dimension, a measure of the severity and frequency of 302 lifetime psychosis, were associated with lower cognitive scores. 303
Performance across the cognitive domains was equivalent in the schizophrenia and 304 schizoaffective depressive groups. These results suggest that from a cognitive 305 perspective, there is questionable validity in the nosological distinction between 306 schizophrenia and schizoaffective depressive. Therapies developed to improve 307 cognition in schizophrenia should also be targeted towards patients with 308 schizoaffective depressive type. These findings also highlight the importance of 309 considering the subtypes of schizoaffective disorder separately, as these groups 310 differed in severity of cognitive impairments. 311
Differences in overall cognition between schizoaffective bipolar and bipolar disorder 312
were not significant after correction for multiple testing. However, the effect size 313 between these groups (d=0.44) was larger than that observed between 314 schizophrenia and schizoaffective depressive (d=0.07). This may explain why a linear 315 trend from bipolar disorder to schizoaffective bipolar to schizophrenia and 316 schizoaffective depressive was still observed in the ordinal regression analysis. We 317 used a conservative Bonferroni-corrected alpha value to control the type-I error rate 318 but at the cost of loss of power, which could explain the lack of significant 319 difference. However, it should be noted that there were smaller differences between 320 schizoaffective bipolar and bipolar disorder on individual domains, which were not 321 significant even at alpha=0.05. 322
Diagnostic groups were differentiated on the basis of severity of cognitive 323 impairments but the overall pattern of impairment was similar between the groups 324 ( Fig. 1 ). This suggests cognitive impairment can be considered a dimensional 325 phenotype that cuts across diagnostic boundaries. These results are consistent with 326 the results of previous studies showing that multiple domains of cognition are 327 affected and these impairments increase in severity from bipolar disorder to 328 schizophrenia [9] [10] [11] [12] . Similarities between the cognitive profiles of these disorders are 329 consistent with a shared underlying neurobiology that differs quantitatively rather 330 than qualitatively across the diagnostic groups 1, 7, 8 . Indeed, previous studies have 331 indicated overlap in regions of grey matter reduction (though less consistently in 332 bipolar disorder) [35] [36] [37] [38] and genetic susceptibility [39] [40] [41] [42] . 333
Whilst neurocognitive impairments were evident across all diagnoses, impairments 334 in social cognition were not present in bipolar disorder but were observed in 335 schizophrenia and schizoaffective disorder. The largest difference between 336 participants with schizoaffective bipolar and bipolar disorder was observed in social 337 cognition suggesting there may be some distinction in the cognitive processes 338 underlying these disorders despite similar neurocognitive profiles. Social cognition 339 was the only domain associated with current positive symptoms. Previous studies 340
have demonstrated associations between domains of social cognition, particularly 341 theory of mind deficits, and psychotic symptoms in schizophrenia [43] [44] [45] . These results 342 suggest that certain social cognitive tasks may differentiate bipolar disorder from 343 other disorders within the bipolar disorder / schizophrenia spectrum. The 344 association between social cognitive impairment and psychosis provides support for 345 cognitive models of psychosis that posit a role for social interpretations in the 346 development of psychotic thinking 46 . Lifetime history of psychosis has been shown to be associated with poorer 352 cognition 17 . Our results expand on these findings by using a dimensional approach to 353 show that lifetime frequency and severity of psychosis predicts severity of cognitive 354
impairments. 355
This study has several strengths. It is one of the largest samples to date and is of a 356 sufficient size to allow us to separate the subtypes of schizoaffective disorder. The 357 sample is well characterised with consensus lifetime diagnoses based on semi-358 structured interview and medical records. The clinical characterisation of the sample 359 allowed us to adjust for the effects of current symptoms and antipsychotic 360 medication, including both current and lifetime antipsychotic exposure. 361
Limitations 362
A number of limitations should be noted. The sizes of the diagnostic groups were 363 uneven and there was a larger sample of participants with schizophrenia than the 364 other disorders. Despite this, our analyses were robust to differences in the group 365 sizes and we were able to detect differences between groups. Our bipolar disorder 366 group consisted of a mixture of patients with and without a lifetime history of 367 psychosis. Given the small number of participants without psychosis, it was not 368 possible to separate the bipolar group into those with and without history of 369 psychosis to examine differences between these groups and schizophrenia or 370 schizoaffective disorder. The MCCB was designed for use with participants with 371 schizophrenia. Previous studies of bipolar disorder have failed to find deficits in 372 executive functioning using the NAB Mazes task 25, 27, 47 . The authors of these studies 373 note that more complex measures of executive function, such as the Wisconsin Card 374
Sorting Task, may be more sensitive to detecting deficits in bipolar disorder. 375
Although our bipolar group was impaired on the NAB Mazes relative to controls, this 376 task may not have been sufficiently complex to differentiate bipolar disorder and 377 schizoaffective disorderbipolar type. Furthermore, our bipolar group was not 378 impaired on the social cognition task (MSCEIT) but previous studies have identified deficits in theory of mind and emotion recognition suggesting that patients with 380 bipolar disorder do have impairments in specific domains of social cognition 48, 49 . 381
Conclusion 382
Using a large and well-characterised sample, we have demonstrated that there is a 383 gradient of increasing cognitive impairment from bipolar disorder to schizoaffective 384 bipolar to schizophrenia and schizoaffective depressive. Differences in cognitive 385 profiles between the diagnoses were quantitative rather than qualitative. Our 386 findings comparing cognition between diagnostic groups confirmed our a priori 387 decision to combine participants with schizophrenia and schizoaffective depressive 388 in the subsequent analyses. This argues against separating schizophrenia and 389 schizoaffective depressive for such analyses. This study was also the first to use a 390 regression model to demonstrate a gradient of cognitive impairment and show that 391 a dimensional measure of lifetime psychotic episodes is linearly associated with 392 cognition. These results provide support for a model of psychotic and affective 393 disorders where diagnostic criteria focus on dimensional measures of symptoms 394 rather than traditional diagnostic categories. 395 Tables   Table 1 Demographic 
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